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Abstract
The Janus kinase (JAK) family, notably JAK1, JAK2 and JAK3 are recognized as
oncogenic drivers in high risk Acute Lymphoblastic Leukemia (ALL). The bulk of activating
JAK mutations are thought to occur within functional hot-spots across Janus Homology
(JH) domains. The most frequently mutated regions is the JH2 pseudo-kinase, which
provides a negative regulatory role to the adjacent catalytically active JH1 kinase domain.
Despite the prevalence of JAK activating mutations and a need for new therapeutic
inhibitors, there is a lack of understanding in the allosteric regulation of JAK kinases. Here
we sought to identify mutations involved in driving ALL in the El Paso del Norte population,
comprised of an 80% Hispanic demographic; an ethnic group associated with high-risk
ALL. Using Whole Exome Sequencing, we detected a novel mutation, V666G, localized
within the JH2 domain of JAK1. This mutant is proximal to well-known and characterized
JAK1 activating mutations. Unexpectedly, the V666G mutation resulted in a JAK1 kinasedead like phenotype as indicated by a lack of autophosphorylation and crossphosphorylation by JAK family members. Furthermore, a dominant negative effect of
kinase dead JAK1 (K908A) and the JAK1 V666G mutant occurred across JAK family auto
and cross activation. JAK3 was autoactivated in the absence of JAK1, however, the
presence of inactive JAK1, either K908A or V666G mutations, reduced JAK3 Tyr
phosphorylation. In the context of Interleukin-2 (IL-2) signaling, a dominant negative effect
by JAK1 V666G was observed on downstream effectors. The presence of JAK1 V666G
decreased Tyr phosphorylation on ALL associated JAK3 activating mutants M511I and
A573V. These findings reveal a dominant negative role of JAK1 on JAK3 and support a
mechanism by which JAK1 may regulate JAK3 autoactivation and IL-2 signaling.
vi

Elucidation of the trans-inhibitory interactions between JAK1 and JAK3 may propagate
new ways to allosterically inhibit overactive JAK kinases in cancer.
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Chapter 1: Introduction
1.1 Significance
Cancer exerts the most profound effect on the Hispanic-Mexican-American
population health, as the leading cause of death in the U.S. (1). It is estimated that
Hispanic children are twice as likely to be diagnosed with cancer than their non-Hispanic
counterparts. Moreover, disproportionate health outcomes persist post therapy (2)
indicating a role for molecular etiology of cancer health disparities. One of the most
prominent Hispanic health disparities in cancer occurs in pediatric leukemia incidence,
and mortality (3).
In the U.S, Hispanic children incur the highest rates of leukemia compared to all
other races and ethnicities (4). These rates occur most frequently for Acute Lymphoblastic
Leukemia (ALL) which accounts for 78% of Hispanic childhood leukemia cases (4) and is
second in cancers causing the most deaths in children (5). With current treatment
regimens, 80% of childhood ALL is cured (6). However, a subgroup exhibit refractory or
relapse ALL where the 5-year free survival rate falls to 15-50%. Hispanics show a 5-year
free survival rate for ALL to be 4% lower compared to other children (4).
Current treatment regimens for ALL now include tailoring therapies to fit a
patient’s needs based on molecular genomic signatures. This has enabled patients to
be screened for common activating mutations to predict whether they can benefit from
targeted therapies. For example, ALL patients carrying the fusion gene, Breakpoint
Cluster Region and Abelson (BCR-ABL) are selected for treatment with imatinib, a
tyrosine kinase inhibitor. Currently, Food and Drug Administration (FDA) approved
1

Janus Kinase (JAK) inhibitors are being tested for their clinical efficacy to treat pediatric
B-ALL with JAK activating mutations (7). It is unknown whether Hispanic patients will
benefit equally from targeted therapies against known mutations as there is a lack of
inclusion or participation of minorities in cancer research and clinical trials. Moreover,
less than 2% of genome-wide studies on biospecimens, are from Hispanics (8) and
therefore it is unknown whether actionable mutations are responsible for driving certain
cancer in this population.
El Paso Del Norte embodies a population of 82% Hispanics, primarily of Mexican
origin. According to the Texas Cancer Registry, this demographic is also burdened by the
high childhood leukemia incidence rates as previously discussed (Figure 1). Therefore,
the unique population demographic of the El Paso-Juarez border provides an opportunity
to investigate the complexity of cancer health disparities in Hispanics. Here, we sought to
identify and characterize JAK mutational profiles that emerge in the Hispanic population
to determine novel targets promoting ALL within such high-risk groups.

2

Cancer Type

Figure 1. El Paso County Childhood Average Cancer Incidence. Distribution of El Paso childhood incidence by cancer
classification. Each section of the diagram represents the percent of childhood cancer incidence within El Paso county.
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1.2 Background
1.2.1 Interleukin 2 Signaling
JAK kinases take the forefront working immediately downstream of cytokine
receptors lacking intrinsic catalytic activity. The JAK family consists of four tyrosine
kinases (JAK1, JAK2, JAK3, and Tyrosine-protein kinase 2 (TYK2)) and through paired
combinations with seven Signal Transducers and Activators of Transcription (STAT)
orchestrate cell specific cytokine signaling (9). Unique to lymphocytes, the common
gamma chain (γc) receptor recruits JAK3 partnered with JAK1 and together transduce
signals from cytokines, Interleukin 2 (IL-2), IL-4, IL-7, IL-9, IL-15 and IL-21 (10).
IL-2 is vital in controlling the life of lymphocytes. The IL-2 ligand is a four-alpha
helical structure that signals by engagement with the IL-2 heterotrimeric receptor (11). IL2 receptor consists of IL-2 receptor β-chain (IL-2Rβ) (CD122), IL-2Rα (CD25) and the γc
(CD132) (12). The high-affinity IL-2Rα/β/γc receptor recruits JAK1 to IL-2Rβ and JAK3
to γc via box1 and box2 motifs. IL-2 binding induces trans-phosphorylation between the
JAK kinases leading to their activation. Once active, JAK kinases phosphorylate Tyr
residues of the γc and IL-2Rβ chain, thereby creating docking sites for Src Homology 2
(SH2) containing proteins. These docking sites allow protein protein interactions
triggering the Mitogen activated protein Kinase (MAPK), Phosphatidylinositol 3 Kinase
(PI3K) and the JAK/STAT pathways. These ladder pathways directly regulate growth,
survival and proliferation respectively.
MAPK Pathway
SH2 containing protein (SHC) binds to phosphorylated Tyr 338 of IL-2Rb chain
4

initiating the MAPK pathway (13). SHC becomes Tyr phosphorylated and recruits Growth
factor receptor-bound protein 2 (GRB2). GRB2 works as an adapter protein for Son of
seven less (SOS). SOS facilitates activation of RAS by the exchange of GDP to GTP.
Now in its active form RAS enables the Ser/Thr kinase RAF to activate Ser/Thr kinase
MEK. MEK phosphorylates MAPK and Extracellular signal regulated protein kinase
(ERK). Next, ERK phosphorylates and activates cytoplasmic and nuclear proteins,
notably transcription factors involved in proliferation. This includes among others C-JUN
and ETS domain containing protein (ELK1), that leads to the expression of Fos. Jun and
Fos then form the AP-1 heterodimer that function as a transcription factor for key cellcycle proteins, including D-type cyclins (14).
PI3K Pathway
Similarly, SHC binds to phosphorylated Tyr 338 of IL-2Rb chain initiating the
Phosphatidylinositol 3 Kinase (PI3K) pathway (15). RAS interacts with the PI3K to induce
its activation. Once active, PI3K phosphorylates lipid Phosphatidylinositol-4,5diphosphate (PIP2) thereby converting it to Phosphatidylinositol-3,4,5-triphosphate
(PIP3). Next, PIP3 recruits phosphoinositide dependent protein kinase 1 (PDK1) that in
turn phosphorylates protein kinase B (AKT). Finally, AKT phosphorylates and activates
proteins involved in survival, and proliferation. Among others, this includes Murine double
minute (MDM2) that regulates p53 tumor suppressor; Forkhead box O involved in
proliferation and mammalian Target of Rapamycin (mTOR), a kinase implicated in
translation and cell growth (16).
JAK/STAT Pathway
5

In response to IL-2, STAT5A and STAT5B bind to phosphorylated Tyr (pY)
residues pY338, pY392 and pY510 of IL-2Rβ and become Tyr phosphorylated
themselves at Y694 and Y699, respectively (17). STAT5A/B then dissociate from their
signaling receptor to form dimers, translocate to the nucleus, and then bind to promoter
sites on multiple genes that control proliferation and survival. Among others this includes,
cyclin D2 involved in proliferation, B-cell lymphoma-extra large (BCL-XL) involved in cell
survival and c-MYC involved in the escape from differentiation (18). Taken together IL-2
induces activation of the most recognized oncogenic signaling pathways, MAPK, PI3K
and JAK/STAT. Expectedly, Tyr phosphorylation within IL-2 signaling is under tight
control by both extrinsic and intrinsic regulation of the JAK kinases (19)
1.2.2 JAK Regulation
The JAK structure consists of seven Janus Homology (JH) domains including JH1JH7 shared across the JAK kinase family JAK1, JAK2, JAK3 and TYK2 (20). JH1 harbors
the kinase domain involved in catalytic activity. JH2 consists of a pseudo-kinase domain
that is structurally similar to JH1 but lacks key residues involved in catalytic activity.
Importantly, JH2 is thought to directly interact with JH1 domain to inhibit overall JAK
activity. JH3-JH7 consist of the 4.1R, Ezrin, Radixin, Moesin (FERM) and Src Homology
2 (SH2) domain and are important for JAKs interacting with their receptor.
JAK Intrinsic regulation
Major progress has been made in understanding the intrinsic regulation of the JAK
kinase family by structural studies on JAK1 JH2 domain. This structure lead to the
identification of the F-F-V triad within JAK1 JH2 that can act as a conformation switch for
6

activation (21). Furthermore, the cis interaction between the pseudokinase and kinase of
TYK2 (22) has provided a model of inhibitory contact sites for understanding intrinsic
negative regulation in cis between the JH1 and JH2 domains. This template of TYK2
inhibitory interactions has lead others to model and predict additional inhibitory interaction
sites within JAK1 (23). Others have proposed models of JH2 transinhibition, where
partner JAKs interact between JH2 and JH1 domains where the JH2 of one JAK inhibits
the JH1 of the other JAK (19). Support for both modes of action are seen throughout the
literature and perhaps these two mechanisms are utilized in context specific JAK/STAT
signaling.
JAK Extrinsic regulation
As discussed previously the JAK kinases are essential in performing
phosphorylation for the IL-2 receptor controlling the activity, localization, and interactions
of proteins along the cascade. The JAK kinases also undergo phosphorylation either by
a partner JAK or themselves to effect their signaling abilities. Therefore, phosphorylation
of key residues along the JAK kinases act as regulators for their catalytic function.
Notably, a Tyr in the activation loop of the JAKs and across the general kinase family
must undergo phosphorylation for full activation. Thus, one way of regulating a tyrosine
kinase extrinsically is via Tyr dephosphorylation. The SH2 Containing Phosphatases
(SHP1) and (SHP2) catalyze the dephosphorylation of TYK2, JAK1 (24) and JAK1, JAK2
(25) respectively. Protein Tyrosine Phosphatases 1B (PTP1B) interacts with substrates
TYK2 and JAK2 via their SH3 domains where they subsequently undergo
dephosphorylation (26). In lymphocytes, T-Cell Protein Tyrosine Phosphatase (TCPTP)
7

dephosphorylates JAK1 and JAK3. CD45, a receptor tyrosine phosphatase, is capable of
dephosphorylating all four JAKs (27).
Other mechanisms for JAK regulation include substrate mimicry by Suppressor of
Cytokines Signaling (SOCS1) and (SOCS2). The SOCS proteins contain a Kinase
Inhibitory Region (KIR), a short motif, that directly interacts with the JAKs as a false
substrate (28) SOCS1 and SOCS3 can also interact with JAKs and several receptors via
their SH2 domains creating steric hindrance. Additionally, SOCS initiate the degradation
of JAKs and linked receptors via ubiquitination events.
1.2.3 Tyrosine Kinases and Leukemia
Negative regularity mechanisms are in place for tight control of Tyr phosphorylation
and or activation of JAK kinases and IL-2 signaling. However, mutagenesis can override
these normal cellular controls and promote constitutively active signals and cancer. Select
leukemias harbor recurrent chromosomal translocations or somatic point mutations that
activate oncogenic tyrosine kinases, leading to constitutive cell signaling. Notably,
constitutive phosphorylation of STAT5A/B is a common outcome from mutated tyrosine
kinases including: BCR-ABL, mutated forms of Fms-Like Tyrosine Kinase Receptor-3
(FLT3), c-Kit (tyrosine kinase), Tel (ETS transcription factor)-JAK2 and the JAK1 V568F
and JAK2 V617F mutants (Figure 2) (29, 30, 31, 32, 33, 34). This is expected because
STAT5A/B are critical for lymphoid survival and are normally activated by common γc
cytokines including the aforementioned IL-2 (35).
JAKs and Acute Lymphoblastic Leukemia
The JAK kinase family, notably JAK1, JAK2 and JAK3 are becoming well
8

recognized as oncogenic drivers in high risk Acute Lymphoblastic Leukemia (ALL),
contributing to a conserved 10.7% of cases (36). ALL is a rapid disease progressing
cancer of immature lymphocytes. One of the most aggressive leukemias of the B-ALL
subtype, is PH-Like ALL associated with high relapse and low survival (37). Although PHLike ALL is defined by a variety of genetic signatures, most are driven by activating the
JAK/STAT pathway (37). Similarly, relapsed T-ALL has been linked to oncogenic JAKs
(38, 39). Regardless of the ALL subtype, aberrant activation of the JAK/STAT pathway by
driver mutations found within the JAKs are likely to become actionable mutations.
JAK Activating Mutations
The bulk of activating mutations in JAK family members occur within functional hotspots typically conserved across JH domains. The most frequently mutated region
amongst the JAKs is the JH2 pseudo-kinase domain, that provides negative regulation of
the active JH1 kinase domain. For example, JAK1 V658F mutation is found in the JH2
domain and occurs in high-risk PH-like B-ALL (40). This Single Nucleotide Polymorphism
(SNP) is analogous to the well-known V617F of JAK2 that drives over 90% of
Polycythemia Vera cases (41). JAK3 also contains high frequency activating mutations in
T-ALL including M511I (42) occurring in the SH2-JH2 linker, and A573V in the JH2 domain
(43). Taken together, these highly conserved domains when mutated similarly affect JAK
kinase activity due to their structural homology. As mentioned previously it is unknown
whether high risk Hispanic ALL patients carry similar or novel JAK activating mutations
that could potentially benefit from pipeline targeted therapies.

9

Chapter 2: Identification of the JAK1 V666G mutation in ALL patient samples
2.1 Introduction
Cancer is the number one cause of death for Hispanics (1). Within these cancers,
an unequal burden of leukemia incidence and mortality exists amongst Hispanic children
(3). ALL patient outcomes have improved with targeted therapies, yet it represents the
second cause of cancer deaths in children (44). Hispanic children have the highest ALL
incidence rates and fair far worse than their non-Hispanic counterparts post therapy (45).
This is in part due to the lack of inclusion of minorities in cancer research and fully
understanding this disease (2). Until we understand how these molecular pathways are
“hijacked” in high-risk ALL, it will be difficult to develop new therapies to end cancer health
disparities.
Recently, newly developed molecular and genetic technologies have become
available to determine driver mutations that result in cancer. Indeed, mutations in kinases
have been known to drive certain leukemias; thus, there has been substantial enthusiasm
for therapies that target oncogenic tyrosine kinases. The JAK tyrosine kinases are
becoming recognized as oncogenic drivers in high risk ALL. However it is unknown
whether Hispanic ALL patients display genomic signatures associated with overactivation
of the JAK/STAT cascade.
The overall objective of this study was to identify SNPs involved in driving ALL in
the El Paso Del Norte population. The goal of this aim was identify novel SNPs in JAK
STAT and regulatory effectors from local ALL patient samples. It was hypothesized that
El Paso Del Norte ALL patient samples contain frequent mutations in the JAK/STAT
10

signaling cascade that results in dysregulation to promote leukemogenesis. The rationale
for this hypothesis is based on studies showing that overactivation of the JAK/STAT
cascade is linked with high rates of relapse in ALL.
2.2 Materials and Methods
2.2.1 Patient Samples WES
Data on the genomic DNA from a small cohort of 7 healthy controls and 9 patients
diagnosed with ALL from the cancer biorepository at UTEP was used to identify the
V666G JAK1 mutant. These data had been previously obtained along with other types of
cancer samples and used to establish OncoMiner, a bioinformatics pipeline for the
analysis of exonic sequence variants in cancer at UTEPs BBRC bioinformatics core (46).
Briefly, DNA was isolated using Purgene Kit A (Qiagen) according to manufacturer’s
instructions and sent to Otogenetics for whole exome sequencing (WES) (46).
2.2.3 OncoMiner
Subsequently, OncoMiner was used to identify and sort through deleterious
genetic variations, including non-synonymous mutations, insertions and deletions.
OncoMiner information was gathered for each SNP regarding gene classification,
genomic location, available publications on the gene/SNP and a Protein Variation Effect
Analyzer (PROVEAN) Score. The PROVEAN score was used to predict deleterious
effects of mutations on protein function with a recommended cut off value of -2.5 (47).
2.3 Results
2.3.1 Identification of the JAK1 V666G mutation in ALL patient samples
ALL patient samples were collected from El Paso Del Norte, stored at the UTEP
11

Tissue Biorepository and sent for WES. SNPs that occurred at least once were 9,967 in
controls and 40,561 in ALL patient samples (Figure 2A). SNPs that were unique to ALL
were sorted by protein classes (48) using gene ontology (GO) terms (49) and the
frequency of each class is represented in the pie with sub levels extending outward
(Figure 2B). Complementary to these data, the 9 ALL Patient (P1-P9) SNPs occurring
within JAK STAT associated genes that were not present in controls are shown in a
heatmap. Patient 4 (P4) shows high frequency mutations in genes implicated in the JAK
STAT pathway. One of these SNPs being the JAK1 V666G mutation that is shown with
its PROVEAN score of -6.8 analyzed by OncoMiner (Figure 3A). The JAK1 V666G SNP
is unreported to our knowledge given its absence in the literature and in our brief search
of cancer databases. This search included the Catalogue Of Somatic Mutations In Cancer
(COSMIC) database that compiles mutations from cancer patients across multiple
databanks including The Cancer Genome Atlas (TCGA) and Genomic Data Commons
(GDC) Portal. Lastly, the JAK1 V666 residue within the JH2 is highly conserved amongst
the JAK family and across species (Figure 3B) signifying its likely relevance on JAK
protein function.
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Patients (P1-P9) are shown with uniquely occurring ALL SNPs within genes involved in
the JAK STAT pathway and represented in a heatmap. Patient 4 contains JAK1 V666G
shown with relevant SNP information including Provean score. B) Val 666 of JAK1 is
highly conserved across JAK family and species.
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2.4 Discussion
Although these data are from a small cohort we detected a high frequency of SNPs
in JAK/STAT associated genes to occur in primarily one ALL patient. This patient
contained both novel and reported SNPs within JAK/STAT genes. As mentioned
previously, Hispanic samples are insufficiently available or absent in Biobanks and thus
consequently underrepresented in clinical research. Here we detected a novel SNP within
JAK1 that was not previously reported in any established cancer databases.
Our group identified V666G in human JAK1, occurring at a highly conserved
residue within the JH2 domain. The potential significance of JAK1 V666G mutation
prompted our interest due its location within the JH2/pseudokinase domain, a known hot
spot for activating mutations. Specifically, JAK1 V666G is located within the JH2 hinge in
close proximity to well-known JAK1 activating mutant V658F. Thus, JAK1 V666G, was
chosen as a candidate for subsequent investigations for its regulation of JAK/STAT
proteins and cell activity.
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Chapter 3: Auto and Cross-Phosphorylation of JAK1 is lost by V666G
3.1 Introduction
Autophosphorylation is a shared mechanism of tyrosine kinases.

It is not

surprising that overexpression of JAK1, JAK2, JAK3 and TYK2 can lead to cytokine
independent growth and constitutive STAT activation (50). This is because many kinases
when expressed at high protein volume become phosphorylated and consequently
activated (51). Accordingly, to detect the activating potential of the JAK1 V666G mutant
we assessed tyrosine phosphorylation in response to conventional overexpression and
kinase assays.
Many JAK kinases rely on partner JAKs to undergo phosphorylation and it is
therefore useful to assess cross-phosphorylation between JAK1 V666G with partner JAK
kinases. The dominant role between JAK kinases in transactivation is an ongoing pursuit
in pathway specific contexts. However, the cross activation between JAK kinases solely
by overexpression is largely unexplored. Therefore, we assessed the potential of the
JAK1 V666G mutant in its ability to phosphorylate partner JAKs and vice versa.
The goal of this aim was to biophysically characterize the impact of JAK mutant
proteins on auto and cross-phosphorylation. It was hypothesized that the newly identified
V666G mutation would enhance activation of JAK1. The rationale for this hypothesis is
based on studies showing that a disruption in the JH2, negative and regulatory,
pseudokinase domain can lead to an oncogenic JAK kinase.
3.2 Materials and Methods
3.2.1 Cell Culture
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The JAK1 deficient, human U4C cell line was grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum ((FBS); Atlanta
Biologicals), 2mM L- glutamine (Corning), and 1% penicillin/streptomycin (Corning).
3.2.3 Plasmids and Site-directed Mutagenesis
The human JAK1 MYC tag (RC213878), JAK1 GFP tag (RG213878) JAK2
(RC220503) and JAK3 (pcDNA3.1) plasmids were purchased from Origene. STAT5B
cDNA, was obtained from the home laboratory originally purchased from OriGene as
described previously (52). Mutant forms of JAK family were prepared using the
QuikChange XL site-directed mutagenesis kit (Agilent) according to the instructions of the
manufacturer. The primers used for the following JAK family mutants are indicated in the
table immediately below (Table 1). All subclones and mutations were verified by DNA
sequencing at the Genomic Analysis Core Facility of the BBRC, at UTEP.
Table 1. JAK1 Mutational Primers
GENE
JAK1

FORWARD

REVERSE

V666G

5'-CGTGGAGAATATCATGGGGGAAGAGTTTGTGGAAG-3'

5'-CTTCCACAAACTCTTCCCCCATGATATTCTCCACG-3

K908A

5'AGGGGAGCAGGTGGCTGTTGCATCTCTGAAGCCTG3'

5'CAGGCTTCAGAGATGCAACAGCCACCTGCTCCCCT3'

3.2.4 Transfections
Approximately 16 hours pre-transfection U4C cells were seeded into 10 cm
dishes to yield 90–95% confluency at the time of transfection. For all following
experiments, cells were transfected with approximately 15μg of indicated JAK plasmid
along with 10μg of STAT5B. MYC tagged JAK1 WT and JAK1 constructs, including
kinase dead (K908A) and V666G along with STAT5B were transfected in U4C cells and
used for overexpression of JAK1 and kinase assays. Similarly, for cross activation of
JAK1 with JAK family members, cells were transfected with JAK1 WT GFP tag, JAK2
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WT, or JAK3 WT with STAT5B either alone or with JAK1 WT MYC tagged or JAK1
MYC tagged constructs K908A or V666G. All transient transfections of U4C cells were
performed according to manufactures instructions, (Lipofectamine 2000, Invitrogen).
Cells were harvested 24 hours post-transfection and subsequently pelleted, lysed,
clarified and immunoprecipitated (IP) with either Origene antibody against GFP tag
(TA150041), or Santa Cruz antibodies against c-MYC (sc40), JAK1 (sc376996) JAK2
(sc390539) or using a polyclonal antibody generated against the COOH terminus of
JAK3 described previously (53).
3.2.5 Kinase Assay
For kinase assays, JAK1 was IP using indicated antibody as described above.
IP protein was washed with kinase buffer (10mM Mops, 3mM EDTA, 001% Triton, 5%
Glycerol, 01% Bme, 1mg/ml BSA, and 10mM MgCl2, at 7 PH) and either incubated in
kinase buffer or kinase buffer supplemented with 100 μM ATP. Kinase reactions were
carried out at 32 °C for 20 min followed by vigorous washing of the beads with cold
kinase buffer followed by a lysis buffer wash and the reaction stopped immediately by
adding 4X Sample Buffer.
3.2.6 Western Blots
Samples were separated by 7.5% or 10% SDS-PAGE and transferred to a
polyvinylidene difluoride (PVDF) membrane (Millipore) for Western Blot (WB) analysis
as previously described (53). Briefly, membranes were probed overnight with mouse
monoclonal anti-phosphoTyr (pTyr) antibody (4G10, EMD Millipore) in
immunoprecipitation experiments and developed using horseradish peroxidase18

conjugated goat anti-mouse and visualized by chemiluminescence using LICOR and
Image Studio Lite software. Membranes were stripped and re-probed for JAK1 (sc295,
Santa Cruz) JAK2 (06-1310, Millipore) or JAK3 (ab78116-100, Abcam). Similarly,
membranes were probed against pTyr STAT5 (05-495, Millipore) for corresponding
lysate when indicated and reprobed for total STAT5 (610191, BD-Transduction).
3.3 Results
3.3.1 Autoactivation and STAT5 Phosphorylation is lost in JAK1 V666G
To investigate the impact of V666G on JAK1 kinase activity we examined
autoactivation by overexpression and measured Tyr phosphorylation of JAK1 and STAT5
substrate. Compared to JAK1 WT, autoactivation of JAK1 V666G was similar to that of
kinase dead control K908A, with significant decreases in Tyr phosphorylation (Figure 4A).
Compared to JAK1 WT, JAK1 V666G Tyr phosphorylation of STAT5 was significantly
decreased, similar to kinase dead (Figure 4B). JAK1 V666G was then challenged by
kinase assay and even in the presence of ATP, Tyr phosphorylation was reduced similar
to kinase dead when compared to WT (Figure 4C).
3.3.2 Cross-activation of JAK1 is lost by V666G mutation and impairs Tyr
Phosphorylation of WT JAK1 JAK2 and JAK3
To investigate whether JAK1 V666G

could be activated by WT JAK family

members we examined cross-activation by overexpression of JAK1-MYC constructs
along wither either WT JAK1-GFP, JAK2 or JAK3 and measured Tyr phosphorylation of
both JAKs. Similar to kinase dead JAK1, JAK1-MYC V666G could not be phosphorylated
by JAK-GFP WT. However, in the presence of MYC tagged kinase dead JAK1 and, JAK1
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V666G, Tyr phosphorylation of JAK1-GFP WT was significantly decreased compared to
samples with either no MYC tagged JAK1 or JAK1-MYC WT. There was no significant
difference in Tyr phosphorylation of JAK1-GFP between that with no JAK1-MYC and
JAK1-MYC WT (Figure 5A). JAK1-MYC V666G could not be phosphorylated by JAK2
WT. In the presence kinase dead JAK1 and, JAK1 V666G, Tyr phosphorylation of JAK2
WT was significantly decreased compared to samples with either no JAK1 or JAK1 WT.
Tyr phosphorylation of JAK2 was significantly greater in the presence of JAK1 WT
compared to no JAK1 (Figure 5B). JAK1-MYC V666G could not be phosphorylated by
JAK3 WT. Again, in the presence of kinase dead JAK1 and, JAK1 V666G, Tyr
phosphorylation of JAK3 WT was significantly decreased compared to samples with
either no JAK1 or JAK1 WT. Furthermore JAK3 with no JAK1 was Tyr phosphorylated to
the same extent as JAK3 in the presence JAK1 WT (Figure 5C). Taken together, neither
WT JAK1, JAK2 or JAK3 were capable of phosphorylating JAK1 V666G. And in the
presence of kinase dead JAK1 K908A and JAK1 V666G autophosphorylation and or
cross-phosphorylation of WT JAK1, JAK2 and JAK3 was significantly reduced.
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Figure 4. Autoactivation and STAT5 Phosphorylation is lost in JAK1 V666G. Immunoblotting in U4C cells,
non-transfected (NT) or transiently transfected to overexpress either JAK1 Wild Type (WT), or JAK1 MYC
constructs, kinase dead (K908A) or JH2 mutant (V666G) along with STAT5. Representative blots are shown with
quantified phosphorylation normalized to total protein using densitometry were N=3. A) Overexpressed JAK1 was
immunoprecipitated (IP) to assess autoactivation indicated by JAK1 Tyr phosphorylation. Data represent means ±
SEM; n = 3 independent experiments.***P <0.0001 using a one-way ANOVA with post-hoc Tukey's test for multiple
comparisons. B) Corresponding lysate was used to assess JAK1 substrate phosphorylation indicated by STAT5
Tyr phosphorylation. Data were analyzed same as A); ***P <0.0001. C) IP JAK1 was challenged by kinase assay
treated with 100 µM ATP for 20 min and blotted for Tyr phosphorylation.

21

B

A

Dis

C

Figure
5.
JAK1
V666G
inhibits
Tyr
phosphorylation of WT JAK1, JAK2 and JAK3.
Immunoblotting in U4C cells, NT or transiently
transfected to overexpress either no JAK1 (-), JAK1
WT-MYC, or JAK1 MYC constructs, K908A or
V666G along with either WT JAK1-GFP, JAK2 or
JAK3. Representative blots are shown with quantified
Tyr phosphorylation normalized to total protein using
densitometry and plotted with mean and ± SEM from
at least 3 independent experiments A) JAK1-GFP
WT was overexpressed with either no JAK1)(-),
JAK1-MYC WT, K908A, or V666G and IP for MYC
and GFP tags subsequently assessed for cross
activation indicated by Tyr phosphorylation. Graphed
data represent JAK1 WT GFP normalized Tyr
phosphorylation n = 4 **P<0.0062 using a one-way
ANOVA with post-hoc Tukey's test for multiple
comparisons. B) JAK2 WT was overexpressed with
either -, JAK1-MYC WT, K908A, or V666G and IP for
JAK1 and JAK2 subsequently assessed for cross
activation indicated by Tyr phosphorylation. Graphed
data represent JAK2 normalized Tyr phosphorylation
n = 3 *P<0.0101, **P<0.0092 P****<0.0001 analyzed
as A). C) JAK3 WT was overexpressed with either -,
JAK1-MYC WT, K908A, or V666G and IP for JAK1
and JAK3 subsequently
assessed for cross
activation indicated by Tyr phosphorylation. Graphed
data represent JAK3 normalized Tyr phosphorylation
n = 3 **P<0.0055 analyzed as A).

22

3.4 Discussion
JAK1 V666G lead to a kinase dead-like phenotype in contrast to our predictions of
overactivation. These observations identified the V666 residue in human JAK1 conserved
across the JAK family as a site necessary for kinase autoactivation.
Additionally, Tyr phosphorylation of JAK1, JAK2 and JAK3, was disrupted
reciprocally by the presence of either the JH1 kinase dead JAK1 mutant or newly
identified JH2 JAK1 V666G mutant. Specifically, the absence of JAK1 allowed minimal
yet sustained autoactivation of JAK2 and moderate activation of JAK1 and JAK3 that
was hindered in the presence of an inactive JAK1. It is likely that JAK2 and JAK3 rather
than autophosphorylate, preferentially cross-phosphorylate with JAK1. Furthermore,
inactive JAK1 inhibited autophosphorylation of JAK1 WT. These data indicate a dominant
negative effect by JAK1 on autophosphorylation and cross-phosphorylation between JAK
family members.
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Chapter 4: JAK1 V666G inhibits JAK3 mediated IL-2 signaling
4.1 Introduction
Understanding the transactivation between partner JAK kinases in common γ
chain signaling is a constant pursuit. One aspect of transactivation includes defining
each role of JAK1 and JAK3 in IL-2 signaling. JAK1 has been recognized for initiating Tyr
phosphorylation of JAK3 in response to IL-2 where JAK3 then reciprocates
phosphorylation (54). Once active, JAK3 takes the bulk action of phosphorylating key Tyr
residues along IL-2Rβ chain (55) creating docking sites for SH2 containing proteins. As
discussed previously (see introduction) these SH2 containing proteins will initiate the
MAPK, PI3K, and JAK/STAT pathways. Pertaining to the JAK/STAT pathway, the SH2
domain of STAT5 binds phosphorylated Tyr along IL-2Rβ chain. This recruitment allows
STAT5 to become phosphorylated mostly by JAK1. For example, containing an active
JAK3 and a kinase-dead JAK1 results in loss of STAT5 phosphorylation and activation
(56).
Similar to a kinase dead JAK1 by JH1 mutation the inactivation of JAK1 via JH2
mutations have been shown to reduce STAT5 basal activity even in the presence of JH1
R657Q JAK3 activating mutant (57). Furthermore JH2 activating JAK3 mutants including
M511I and A573V have been shown to require IL-2 receptor, and JAK1 for their
transforming capabilities (58). It seems that the presence of JAK1 is necessary for JAK3
activation and downstream IL-2 signaling. However, it is unclear if the absence of JAK1
and the presence of inactive JAK1 by JH1 (K908A) and JH2 (V666G) mutations effect
JAK3 activation and IL-2 signaling differently. Deciphering these outcomes could provide
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support for trans-inhibition between JAK kinases and henceforth new ways to extrinsically
target overactive JAKs. Insights into the mechanism of action behind inactive JH2
mutants can also propagate new ways to inhibit JAKs allosterically.
The goal of this aim was to determine the functional impact of novel JAK mutation
V666G on IL-2 signaling with JAK3 WT or activating JAK3 M511I and A573V involved in
ALL. It was hypothesized that the newly identified V666G JAK1 mutant would reduce
JAK3 Tyr phosphorylation and IL-2 downstream signaling. The rationale for this
hypothesis is based on studies showing that IL-2 requires a functional JAK1 kinase for
both WT and oncogenic JAK3 signaling.
4.2 Materials and Methods
4.2.1 Plasmids and Site-directed Mutagenesis,
U4C cell lines were maintained as described previously (Chapter 2).
Complementary to aforementioned JAK1 and JAK3 plasmids, IL-2Rβ, γc, and mutant
M511I and A573V JAK3 (see Table 2) were obtained from the home laboratory as
described previously (59).
Table 2. JAK3 Mutational Primers
GENE
JAK3

FORWARD

REVERSE

M511I

5′-CCAATACCAGCTGAGTCA GATCACACACAAGATCCCTG-3

5′-GAGGGATCTTGTGAAATGT-GATCTGACTCAGCTGG TATTGG-3′

A573V

5′-GTCATTCCTGG AAGCAGTGAGCTTGATGAGCCAAG-3′

5′-CTTGGCTCATCAAGCTCACTGCTTCCAGG AATGAC-3′

4.2.2 Transfections and IL-2
For all following experiments, U4C cells were transfected with 5μg IL-2Rβ, and
5μg γc to reconstitute IL-2 signaling components. In this reconstituted system, the first
set of experiments included 15μg JAK3 WT expressed alone or with JAK1 MYC
constructs (WT, K908A and V666G) and STAT5 and used for immunoprecipitation.
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Complementary to this scheme a separate experiment was conducted using total cell
lysate to examine the effects of JAK1 V666G on IL-2 induced activation of downstream
STAT5, ERK and AKT. This reconstituted pathway included the same experimental
scheme as above with JAK1 MYC constructs and JAK3 adjusted to approximately
500ng to prevent autoactivation and respond to IL-2.
The next set of experiments included 15μg of JAK3 WT or JAK3 constructs
M511I or A573V expressed with either JAK1 MYC WT or V666G, or a combination and
used for IP. The combination was included to assess whether JAK1 WT could rescue
the inhibitory effects of JAK1 V666G. Again, complementary to this scheme, a separate
set of experiments was conducted using lysate to examine the effects of JAK1 V666G
on JAK3 M511I or A573V IL-2 induced activation of downstream STAT5. This
reconstituted pathway included the same experimental scheme with JAK1 MYC and
JAK3 constructs adjusted to approximately 500ng to prevent autoactivation and respond
to IL-2.
Cells used for immunoprecipitation experiments received complete media while
cells used for lysate experiments were made quiescent by receiving 1% FBS media and
incubated for twenty-four hours post transfection. All cells were treated with 400 IU/ml IL-

2 for 10 minutes prior to immunoprecipitation while cells that were made quiescent were
either stimulated with or without IL-2 for 10 minutes and analyzed with lysate. Cells were
subsequently harvested, pelleted, lysed, clarified and either used for

immunoprecipitation or immediately probed for activation. IP JAK1 or JAK3 were
Western blotted for pTyr then stripped and re-probed for total JAK1 or JAK3. Similarly,
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lysate experiments were probed for pTyr STAT5, pERK (Cell signaling, 4370S), or
pAKT (Cell signaling, D25E6), then stripped and re-probed for total STAT5, ERK (Cell
singling 4695) or AKT (Cell signaling, C67E7) where indicated.
4.3 Results
4.3.1 JAK1 V666G inhibits JAK3 mediated IL-2 signaling
We reasoned that a dominant presence of JAK1 V666G on JAK3 WT as seen in
our kinase overexpression studies may translate over in the context of IL-2 signaling. To
investigate whether JAK1 V666G could inhibit JAK3 in the presence of IL-2 and signaling
components, we examined activation of JAK3 and downstream JAK/STAT, MAPK and
PI3K proteins, STAT5, ERK and AKT respectively. Challenged with IL-2, overexpressed
JAK1 V666G showed reduced Tyr phosphorylation compared to JAK1 WT even in the
presence of JAK3 and IL-2 signaling components. In this same context, JAK3 showed a
reduction in Tyr phosphorylation when in the presence of JAK1 V666G compared to that
expressed with no JAK1 or JAK1 WT. A Similar trend in decreased Tyr phosphorylation
occurred in STAT5 from corresponding lysate (Figure 6A).
To determine whether JAK1 V666G could inhibit downstream IL-2 signaling, U4C
cells were transfected with the same scheme as described in Figure 6A with the exception
of expressing the minimum amount of JAK needed to respond to IL-2. Challenged with
IL-2, STAT5 showed a reduction in Tyr phosphorylation in the presence of JAK1 V666G
compared to JAK1 WT. Phosphorylation of ERK and AKT were significantly reduced in
the presence of JAK1 V666G compared to samples with no JAK1 or JAK1 WT (Figure
6B).
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4.3.2 JAK1 V666G inhibits JAK3 M511I and A573V mediated IL-2 signaling.
To investigate whether JAK1 V666G could inhibit activating JAK3 mutants M511I
and A573V, we examined Tyr phosphorylation of JAK3 mutants in response to IL-2.
Challenged with IL-2 overexpressed JAK1 V666G showed reduced Tyr phosphorylation
compared to JAK1 WT even in the presence of M511II JAK3 activating mutant. JAK3
M511I showed a reduction in Tyr phosphorylation when in the presence of JAK1 V666G.
Furthermore, the inhibitory effects of JAK1 V666G could not be rescued by the presence
of JAK1 WT, as decreases in Tyr phosphorylation continued in JAK3 M511I. Likewise,
cells transfected with the same scheme as described above but instead with the minimum
amount of JAK constructs needed to respond to IL-2, JAK1 V666G continued to inhibit
downstream STAT5 phosphorylation of JAK3 M511I in response to IL-2. Even in the
presence of both JAK1 V666G and JAK1 WT, a reduction in Tyr phosphorylation of STAT5
continued (Figure 7A).
Similarly, JAK3 A573V could not phosphorylate JAK1 V666G and revealed
reduced Tyr phosphorylation in its presence. The inhibitory effects of JAK1 V666G could
not be rescued by the addition of JAK1 WT, as decreased Tyr phosphorylation continued
in JAK3 A573V. Likewise, cells transfected with the same scheme described above but
instead with the amount of JAK constructs needed to respond to IL-2, JAK1 V666G
continued to inhibit STAT5 phosphorylation of JAK3 A573V in response to IL-2. In the
presence of both JAK1 V666G and JAK1 WT, a reduction in Tyr phosphorylation of STAT5
continued (Figure 7B). These data demonstrate that “constitutively active” JAK3 mutants
are incapable of activating the JAK1 V666G. Additionally, activating JAK3 mutants cannot
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escape the inhibitory effects of JAK1 V666G even when JAK1 WT is available for rescue.

29

A

B

+
-

JAK3 WT
JAK1 WT MYC
JAK1 K908A MYC
JAK1 V666G MYC

+
+
-

+
+
-

+
+
α pSTAT5
α STAT5

-

+

-

+

-

+

-

+

1.0

0.5

V6
6

K9
0

W
T

8A

6G

0.0

-

STAT5 Normalized Phosphorylation by IL-2

IL-2

JAK1 MYC

+
+
-

+
+
-

+
+
α PERK
α ERK

IL-2

-

+

-

+

-

+

-

+

*
*

1.0

0.5

V6

K9

66

08

W
T

A

G

0.0

-

ERK Normalized Phosphorylation by IL-2

Figure 6. JAK1 V666G inhibits JAK3
mediated IL-2 signaling. Immunoblotting in
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Figure 7. JAK1 V666G inhibits JAK3 M511I and A573V IL-2 signaling. Immunoblotting in U4C cells, NT or transiently
transfected with JAK1 MYC constructs, and M511I or A573V and IL-2 signaling components A) Challenged with IL-2,
overexpressed JAK1 and JAK3 M511I were IP and examined for Tyr phosphorylation in the presence of JAK1 V666G or JAK1
V666G with JAK1 WT rescue. Below, similar to the latter transfection scheme using the minimum of JAK1 and JAK3 constructs
needed for IL-2 induction, lysate was examined for STAT5 phosphorylation B) The same context as (A) but instead expressed
with JAK3 A573V were IP JAKs were examined for Tyr phosphorylation and again below a complementary transfection scheme
showing STAT5 phosphorylation in response to IL-2.
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4.4 Discussion
These findings demonstrate that direct Tyr phosphorylation of JAK1, necessary
for IL-2 signaling, can be disrupted by the presence of a mutation within the JH2 domain.
The exchange of a single amino acid residue Val in the hinge region of JH2 results in a
kinase that is functionally inactive. In conjunction with others we show that an inactive
JAK1 prevents optimal IL-2 induced activation of STAT5 (56). Additionally, JAK1 V666G
abrogates JAK3 Tyr phosphorylation and dominantly impairs IL-2 mediated signaling in
STAT5, as well as ERK and AKT. However, we also show that in the absence of JAK1,
JAK3 can sustain IL-2 signaling indicated by downstream phosphorylation of ERK and
AKT that is reduced in the presence of JAK1 V666G. This finding indicates a direct and
dominant negative effect of an inactive JAK1 by JH2 mutation on JAK3 activity.
Lastly, JAK1 V666G dominant negative effect continues in the presence of JAK3
activating mutants M511I and A573V. These JAK3 mutants constitutively phosphorylate
key Tyr residues along IL-2 receptor and recruit STAT5 to sustain oncogenesis. Here we
show that JAK3 M511I and A573V in the presence of JAK1 V666G decrease their
signaling potential. Others have demonstrated this effect on JAK3 M511I with traditional
JAK1 JH1 kinase dead mutants (58) but here we show the same effect with a JH2 kinase
dead-like mutant V666G. And even with a rescue JAK1 WT present, together expressed
with JAK1 V666G, JAK3 M511I and A573V phosphorylation remains decreased.
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Chapter 5: Future Directions
5.1 Future Directions
It is surprising that a single point mutation within the JH2 could have such a
negative effect on both autoactivation, cross-phosphorylation and IL-2 induced
transphosphorylation. Solved structures for JAK1 and family members were used to aid
in understanding the mechanism of action responsible for JAK1 V666G. As discussed
previously, the cis interaction between the pseudokinase and kinase of TYK2 (22) has
provided a model of inhibitory contact sites between JH1 and JH2 domains. This model
has led others to predict inhibitory interaction sites within JAK1 including an inhibitory salt
bridge located between the pseudokinase hinge 668E and kinase domain loop 893R
(23). Given that our Gly mutation is proximal to this hypothetical salt bridge, the structural
consequence of JAK1 V666G was modeled by superimposing on the TYK2 structure
[Protein Data Bank (PDB) ID code 3NZ0].
The linear structure of JAK1 is shown with JH and established domains where
the V666G location is indicated within the JH2 pseudo-kinase domain and its structural
consequence modeled immediately below (Figure 8). This model reveals its proximity
near the predicted salt bridge at the JH1 and JH2 cis interface.
A couple lines of thought are offered that may explain the inhibitory effect of JAK1
V666G in cis. First, modeled against Canté-Barrett proposed inhibitory salt-bridge the
exchange from Val for Gly may allow flexibility and subsequently strengthen electrostatic
interactions between the JH1 and JH2 interface. Second, recent evidence suggests that
ATP binding within the JH2 of JAK family members provides some form of structural
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stability enhancing JH1 activity (60, 61). Thus, along the lines that ATP bound JH2
facilitates activation, perhaps the presence of V666G disrupts ATP binding and
compromises JH1 stability resulting in an inactive kinase. Future directions include
modeling the binding of ATP to JAK1 JH2 in the presence of V666G. Interestingly, many
FDA approved kinase inhibitors target residues flanking the hinge of the canonical kinase
domains using non-conserved residues for specificity (62). Given the inhibitory effect of
V666G within the JH2 hinge, perhaps this region could similarly be targeted to effectively
inhibit oncogenic JAK1 kinases allosterically.
The ladder interpretations alone do not fully account for the inhibitory effects of
JAK1 V666G on partner JAKs which supports an inhibitory mechanism in trans. To date
there are no crystal structures of partner JAKs interacting in trans so the structural basis
by which separate JH1 and JH2 domains interact is limited. Val 666 is found within the
hinge of the JH2 near the hub of activating mutants, notably V658F (analogous to JAK2
V617F). Proposed by Brooks, the V617F hotspot along with the activation loop in JAK2
JH2 is predicted to interact in trans with the active site of another JAK2 JH1 (63). This
ladder theory is perhaps one of the closest trans-inhibitory interaction one could model
against other JAKs. We propose the V666G mutation strengthens a similar interface
between the JH2 JAK1 and JH1 JAK3. Val 666 is one residue away from the JH2
gatekeeper E667 (64) and the identity of a kinase’s gatekeeper has been shown to
influence the conformational positioning of its activation loop (Hari et al., 2013). Thus, we
speculate that V666G promotes an activation loop extended away from the JAK1 JH2
enhancing its interaction with the active site of JAK3 JH1. Future directions include
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modeling the position of the activation loop within JAK1 JH2 in the presence of V666G.
Structural studies on JAK JH1 JH2 domain interactions are needed to explore the the
mechanistic action of JAK1 V666G. Defining the physical contacts between JAK1 V666G
and JAK3 could reveal new targetable regions against oncogenic JAKs. Importantly, the
residues within this inhibitory interface could very well be outside the JAK3 ATP pocket
that can be exploited by new drugs for allosteric inhibition. It is also speculated that this
highly conserved Val residue may be conserved across other Tyr kinases and
pseudokinases. Future directions, determining if this Val is conserved across such
kinomes could mean that new targetable regions would not be restricted to JAKs.
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Figure 8. JAK1 V666G is predicted to be within the JH1 JH2 cis interface.
Linear model of JAK1 with V666G shown in the JH2 domain and modeled against TYK2 JH1 JH2 inhibitory
interaction. JAK1 V666G within JH2 (orange) at the interface near Glu668 and JH1 (Teal) Asp893 hypothetical salt
bridge (green).
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Chapter 6: Overview
6.1 Overview
To identify how ALL is driving Hispanic health disparities, El Paso Del Norte ALL
patient samples were screened for mutations involved in the JAK/STAT pathway. Using
WES a novel mutation, V666G, in the JH2 of JAK1 was detected. The potential
significance of this JAK1 V666G mutation prompted our interest due its location within
the pseudokinase hinge in close proximity to well-known JAK1 activating mutants.
Unexpectedly, the V666G mutation lead to a kinase-dead like phenotype on JAK1 as
indicated by a lack of autophosphorylation and cross-phosphorylation by JAK family
members. Furthermore, a consistent dominant negative effect of kinase dead JAK1
K908A and the newly identified JAK1 V666G JH2 mutant was seen on JAK family
member cross phosphorylation. Particularly, the absence of JAK1 allowed sustained
autoactivation of JAK3 yet the presence of inactive JAK1 by JH1 and JH2 mutations
could reduce this activity indicated by Tyr phosphorylation. In the context of IL-2
signaling, a dominant negative effect of JAK1 V666G continued upon JAK3
transphosphorylation and downstream signaling. This trans-inhibitory effect of JAK1
V666G continued amongst ALL associated JAK3 activating mutants M511I and A573V.
These findings demonstrate a dominant negative role of JAK1 on JAK3 and support that
JAK1 JH2 domain can directly effect activation of JAK3. As mentioned previously future
directions modeling this inhibitory interaction between the poorly understood JAK1 JH2
pseudokinase and JAK3 could yield insights about how to inhibit oncogenic JAKs.
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